Androgen Deprivation Research Peptides

5 research peptides demonstrate androgen deprivation properties. This collection covers their mechanisms, evidence base, and research applications.

Approved Medication with Strong Human Data | Reproductive / Hormonal

Leuprolide (leuprorelin) is a synthetic GnRH (gonadotropin-releasing hormone) agonist nonapeptide (MW ~1209.4 g/mol) that is one of the most widely prescribed hormonal therapies in oncology and reproductive medicine.

Mechanism: Leuprolide is a GnRH agonist approximately 15-100 times more potent than native GnRH. It operates through a "flare then suppression" mechanism: initial administration causes a transient stimulation ("flare") of pituitary gonadotropin release (LH and FSH surge), leading to a temporary increase in testosterone or estrogen over the first 1-2 weeks. With continuous administration, the sustained agonism causes GnRH receptor downregulation and desensitization of pituitary gonadotrophs, resulting in profound suppression of LH and FSH secretion. Testosterone levels in men fall to castrate levels (<50 ng/dL) within 2-4 weeks, and estrogen levels in women decrease to postmenopausal levels. The D-leucine substitution at position 6 of native GnRH confers resistance to enzymatic degradation and increased receptor binding affinity. Depot formulations use biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres or in-situ gel (Eligard) for sustained release over 1-6 months.

Approved Medication with Strong Human Data | Reproductive / Hormonal

Like other GnRH agonists, goserelin operates through a "flare then suppression" mechanism, achieving castrate levels of sex steroids with continued administration. The implant formulation is available in 1-month (3.6 mg) and 3-month (10.8 mg) presentations.

Mechanism: Goserelin is a GnRH agonist with a D-Ser(tBu) substitution at position 6 and an azaglycine amide at position 10, providing enhanced potency and enzymatic resistance compared to native GnRH. The mechanism follows the "flare then suppression" paradigm: initial administration causes transient stimulation of pituitary gonadotrophs, increasing LH, FSH, and downstream sex steroids (testosterone in men, estradiol in women) for approximately 7-10 days. Continuous GnRH receptor stimulation leads to receptor downregulation and desensitization, suppressing gonadotropin secretion and reducing testosterone to castrate levels (<50 ng/dL) within 2-4 weeks in men, and estradiol to postmenopausal levels in women. The Zoladex implant consists of goserelin dispersed in a D,L-lactic and glycolic acid copolymer matrix that degrades in vivo over 28 days (3.6 mg) or 12 weeks (10.8 mg), providing sustained drug release. Serum goserelin levels peak at approximately 2-3 days post-implant.

Approved Medication with Strong Human Data | Reproductive / Hormonal

Triptorelin is a synthetic GnRH agonist decapeptide analog (MW ~1311.4 g/mol) with a D-Trp substitution at position 6 of native GnRH. Like other GnRH agonists, it operates through initial pituitary stimulation followed by receptor downregulation and gonadotropin suppression.

Mechanism: Triptorelin is a potent GnRH agonist with approximately 100-fold greater potency than native GnRH due to the D-Trp6 substitution, which confers resistance to enzymatic degradation and enhanced receptor binding. The "flare then suppression" mechanism applies: initial doses stimulate pituitary gonadotrophs, causing a transient rise in LH, FSH, testosterone, and estradiol over the first 1-2 weeks. Sustained receptor occupation leads to GnRH receptor downregulation, uncoupling of intracellular signaling, and suppression of gonadotropin release. In prostate cancer patients, testosterone reaches castrate levels (<50 ng/dL) within 3-4 weeks. The depot formulation uses PLGA microspheres (Trelstar) or a sustained-release injectable suspension (Triptodur) to provide continuous drug release. The elimination half-life of the free peptide is approximately 2.8 hours after IV administration.

Approved Medication with Strong Human Data | Reproductive / Hormonal

Histrelin is a synthetic GnRH agonist nonapeptide analog (MW ~1323.5 g/mol) with a D-His(benzyl) substitution at position 6. The hydrogel implant technology provides consistent drug delivery for a full year, offering the longest interval between doses of any GnRH agonist formulation.

Mechanism: Histrelin is a GnRH agonist approximately 100 times more potent than native GnRH due to the D-His(N-benzyl) substitution at position 6, which confers enhanced receptor binding affinity and resistance to enzymatic degradation. Like all GnRH agonists, it operates through the "flare then suppression" mechanism: initial exposure causes transient stimulation of pituitary gonadotrophs with a surge in LH, FSH, and sex steroids lasting approximately 1-2 weeks. Testosterone falls to castrate levels within 2-4 weeks in prostate cancer patients, and prepubertal sex steroid levels are achieved in CPP patients. The implant uses a hydrogel reservoir technology (non-biodegradable) that must be surgically removed after 12 months.

Approved Medication with Strong Human Data | Reproductive / Hormonal

Degarelix is a synthetic GnRH antagonist (MW ~1632.3 g/mol) and the first injectable GnRH receptor blocker approved for advanced prostate cancer. This is clinically significant in patients where testosterone flare could cause complications such as spinal cord compression, urinary obstruction, or bone pain exacerbation.

Mechanism: Degarelix is a synthetic decapeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors without activating them, immediately blocking the release of LH and FSH. Unlike GnRH agonists, antagonists do not cause an initial surge of gonadotropins or sex steroids (no "flare" effect). Testosterone suppression begins within hours of the first injection, with >80% of patients achieving castrate levels (<50 ng/dL) by day 3 and >99% by day 28. The molecule features multiple unnatural amino acids (including D-amino acids and N-methylated residues) that provide high receptor affinity and enzymatic resistance. Degarelix also has demonstrated direct antitumor effects through GnRH receptor antagonism on prostate cancer cells in preclinical studies.